Objective The aim of this study was to assess the frailty status of patients with heart failure undergoing CRT-D and then explore the predictive value of frailty for all-cause mortality and heart failure-related readmissions in these patients.Methods We retrospectively included 374 patients with chronic heart failure who underwent CRT-D treatment at the First Affiliated Hospital of Xinjiang Medical University between June 2020 and June 2024.Based on the Tilburg Debilitation Assessment Scale,175 patients(46.8%)were classified as frail while 199(53.2%)were classified as non-frail.The baseline data between the two groups was compared using Cox regression analysis and Kaplan-Meier curves were used for survival analysis.P-values of<0.05 indicated statistically significant differences.Results A total of 374 patients aged 25-93(68±11)years were enrolled in this study,101(27.0%)of which were female.Among these,175(46.8%)were categorized as frail,and 199(53.2%)were classified as non-frail.Over a median follow-up time of 23(5,45)months,35(9.4%)patients experienced all-cause mortality,with 30(17.1%)deaths occurring in the frail group and 5(2.5%)in the non-frail group;meanwhile,readmission events due to heart failure occurred in a total of 174(46.5%)patients,including 122(70.1%)in the frail group,and 52(29.9%)in the non-frail group.Cox analysis showed that frailty was a significant determinant of all-cause mortality(HR=21.25,95%CI 3.99-113.30,P<0.001)and readmission among heart failure patients receiving CRT-D(HR=2.52,95%CI 1.73-3.68,P<0.001).Log-rank tests showed that the survival rate of patients in the frail group was significantly lower than that of patients in the non-frail group(HR=7.22,95%CI 2.80-18.60,P<0.001)and the risk of readmission events due to heart failure was significantly higher among patients in the frail group than among those in the non-frail group(HR=2.75,95%CI 1.98-3.81,P<0.001).Conclusions Frailty is an independent predictor of postoperative all-cause mortality and the occurrence of heart failure-related readmissions in patients with heart failure treated receiving CRT-D.